Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0638-0355 in Overweight or Obesity
NCT06577766Phase 1Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing NNC0638-0355 with Placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events at 20 weeks. Started Sep 2024; status: active, not recruiting.
02
Drugs
NNC0638-0355
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06577766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577766.